Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. Raiser F, Davis M, Adelglass J, Cai MR, et al. Vaccine 2023;41:5965-5973.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Raiser F, Davis M, Adelglass J, Cai MR, et al. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. Vaccine 2023;41:5965-5973.
PMID: 37652823